denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Special-Interest Sessions
Session: ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Research, Clinical trials, Artificial intelligence (AI), Adult, Lymphoid Leukemias, MDS, ALL, CLL, APL, Clinical Practice (Health Services and Quality), Elderly, MPN, Translational Research, Clinical Research, Health outcomes research, Bioinformatics, Chronic Myeloid Malignancies, Patient-reported outcomes, Diseases, Real-world evidence, Registries, Lymphoid Malignancies, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Session: ASH Research Collaborative Multiple Myeloma Network: Accelerating Research and Collaborative Clinical Care through Real-World Evidence Generation
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Research, Clinical trials, Artificial intelligence (AI), Adult, Lymphoid Leukemias, MDS, ALL, CLL, APL, Clinical Practice (Health Services and Quality), Elderly, MPN, Translational Research, Clinical Research, Health outcomes research, Bioinformatics, Chronic Myeloid Malignancies, Patient-reported outcomes, Diseases, Real-world evidence, Registries, Lymphoid Malignancies, Myeloid Malignancies, Technology and Procedures, Study Population, Human, Measurable Residual Disease
Saturday, December 7, 2024, 4:00 PM-5:30 PM
Disclosures: Hernandez Rivas: GlaxoSmithKline: Consultancy, Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau.